Evidence map›Paper›PMID 21507707›Full record

ReviewCurrent opinion in chemical biology2011

Materials from peptide assembly: towards the treatment of cancer and transmittable disease.

Monica C Branco, Dina M Sigano, Joel P Schneider

Abstract readReview
In one paragraph

Review in Current opinion in chemical biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Dynamic Continuum of Molecular Assemblies for Controlling Cell Fates.Chembiochem : a European journal of chemical biology · 2019
    Article
  11. Assemblies of Peptides in a Complex Environment and their Applications.Angewandte Chemie (International ed. in English) · 2019
    Review
  12. Review
  13. Article
  14. Article
  15. Antimicrobial activity of a porphyrin binding peptide.Peptide science (Hoboken, N.J.) · 2018
    Article
  16. Review
  17. Article
  18. Three-DimensionalFrontiers in pharmacology · 2018
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Monica C BrancoChemical Biology Laboratory, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
Dina M Sigano
Joel P Schneider

Funding

Design and Utility of Novel Protienaceous BiomaterialsZIABC011313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHNEIDER, JOEL · 2010 to 2025
$19.0M
Development of antibacterial agents and materialsZIABC011314 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHNEIDER, JOEL · 2010 to 2025
$8.9M
Intramural NIH HHS ZIA BC011313Intramural NIH HHS ZIA BC011314
6 · The paper itself

Abstract

As the prevalence of cancer and transmittable disease persists, the development of new and more advanced therapies remains a priority in medical research. An emerging platform for the treatment of these illnesses is the use of materials formed via peptide assembly where the bulk material itself acts as the therapeutic. Higher ordered peptide structures with defined chemistry are capable of cellular targeting, recognition, and internalization. Recent design efforts are being made to exploit the nanoscale definition of the materials formed by assembling peptides to target cancer and microbial cells and to function as vaccines. This review focuses on assembled peptide materials that actively participate in the biological processes important to cancer and transmittable diseases to exert an anticipated functional outcome.

Indexed as

Drug DesignAnimalsCancer VaccinesCommunicable DiseasesHumansNeoplasmsPeptidesCancer VaccinesPeptides

Identifiers

PMID21507707
PMCPMC3489472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.